Results 111 to 120 of about 14,162 (232)

A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds

Health Science Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background and Aims Acne vulgaris is a frequent skin disorder, affecting a large part of the population worldwide, and strongly influencing not only the physical but also the mental aspects of health. The choice of therapy for acne vulgaris is a very difficult one because the multifactorial causality of the disease and interindividual ...
Mobina Tajdari, Setare Abolghasemi, Elham Khanniri, Maryam Bayanati, Rahil Hakimimofrad, Mohammad Mahboubi‐Rabbani   +5 more
wiley   +1 more source

Beyond BMI: Practical Guide for Clinicians to Integrate the Lancet Commission's Obesity Framework and King's Obesity Staging System

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT Body mass index (BMI) on its own is a poor diagnostic and staging tool for obesity because it does not measure health status. The newly published Lancet Clinical Obesity Criteria (LCOC) for defining clinical obesity distinguish preclinical and clinical obesity based on organ or tissue dysfunction.
Tak Ying Louise Ko, Alexander D. Miras, Dimitri J. Pournaras, Carel W. Le Roux   +3 more
wiley   +1 more source

Hidradenitis suppurativa patient requiring cardiac procedure with inguinal access: Case management with ertapenem

SAGE Open Medical Case Reports
Hidradenitis suppurativa is a chronic inflammatory skin disease that usually presents in young adults with painful abscesses in intertriginous areas.
Laurence Mainville, Jimmy MacHaalany, Hélène Veillette   +2 more
doaj   +1 more source

Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils [PDF]

, 2020
Shanthi Narla, Martin J Azzam, Steven M. Townsend, Gautham Vellaichamy, Angelo Valerio Marzano, Afsáneh Alavi, Michelle A. Lowes, Iltefat Hamzavi   +7 more
openalex   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

MSC‐Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges—A Narrative Review

International Journal of Dermatology, Volume 65, Issue 2, Page 257-272, February 2026.
ABSTRACT Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell‐based therapies.
Marcela da Costa Pereira Cestari, Reinaldo Falavigna Tovo, Daniela Franco Bueno   +2 more
wiley   +1 more source

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?

Clinical and Experimental Gastroenterology, 2020
Rodrigo Fedatto Beraldo,1 Mariana Barros Marcondes,1 Julio Pinheiro Baima,1 Jaqueline Ribeiro Barros,1 Madhoor Ramdeen,2 Rogerio Saad-Hossne,3 Ligia Yukie Sassaki1 1Department of Internal Medicine, São Paulo State University (Unesp), Medical ...
Beraldo RF, Marcondes MB, Baima JP, Barros JR, Ramdeen M, Saad-Hossne R, Sassaki LY   +6 more
doaj  

Migraine is not the most common comorbidity in hidradenitis suppurativa patients

, 2019
Nicolas Kluger, Pauliina Nuutinen, Emilia Lybeck, Timo Ruohoalho, Alexander Salava   +4 more
openalex   +2 more sources

Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies

International Journal of Dermatology, Volume 65, Issue 2, Page 289-298, February 2026.
ABSTRACT Background Secukinumab, a fully human, monoclonal antibody targeting interleukin‐17A, is approved for moderate‐to‐severe HS in adults. This study evaluated pharmacokinetics (PK), high‐sensitivity C‐reactive protein (hsCRP) changes, and safety of secukinumab over 52 weeks in SUNSHINE and SUNRISE Phase 3 trials.
Afsaneh Alavi, Ziad Reguiai, Gregor B. E. Jemec, Alice B. Gottlieb, Magdalena B. Wozniak, Lorenz Uhlmann, Heng Fan, Angela Llobet Martinez, Gerard Bruin, Nicolas Thomas, Ivette Alarcon, Bruno Bieth, Shoba Ravichandran, Alexa B. Kimball   +13 more
wiley   +1 more source

No Human Leukocyte Antigen-A, -B or -DR Association in Swedish Patients with Hidradenitis Suppurativa

, 2001
Jan Lapins, Olle Olerup, Lennart Emtestam   +2 more
openalex   +1 more source